Reducing Turnaround Time And Cost In Cell Therapy Manufacturing Through Integrated At-Line Immunophenotyping QC

By Harish Adoni, Senior Scientist, Analytical Development

This work highlights a streamlined strategy to reduce both turnaround time and operational costs in cell therapy manufacturing by integrating automated at‑line immunophenotyping QC directly into the production workflow. The approach addresses common bottlenecks in quality control, where conventional methods are often labor‑intensive, time‑consuming, and costly. By adopting an automated workflow capable of handling variable sample matrices—such as those encountered during cell isolation and activation—the method demonstrates strong alignment with traditional flow cytometry, showing well‑resolved populations and reliable quantification.

The integrated system also supports scalability, enabling faster analytical cycles and more consistent QC outcomes. This reduces delays, enhances process reliability, and helps ensure that cell therapy products meet critical quality attributes throughout manufacturing. Overall, the work illustrates how modernized analytical strategies can significantly improve efficiency in cell therapy production while maintaining rigorous scientific and regulatory standards.